Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
- CAS Registry Number
- Not verified
- Molecular formula
- Not verified
- Molecular weight
- Not verified g/mol
- Drug class
- CD123-directed antibody-drug conjugate (ADC)indolinobenzodiazepine DNA-alkylating antineoplastic
- Mechanism of action
- Pivekimab sunirine is a humanised anti-CD123 IgG1 antibody-drug conjugate. After binding to CD123-expressing cells and internalisation, intracellular processing releases the FGN849 indolinobenzodiazepine pseudodimer payload, which alkylates DNA, causes DNA strand breaks and induces apoptosis and cell death.
- Indications / reported uses
- Treatment of adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), under the US product indication approved in May 2026.
Sources: https://www.fda.gov/drugs/cancer-approvals/fda-approves-pivekimab-sunirine-pvzy-blastic-plasmacytoid-dendritic-cell-neoplasm-ultra-rare · https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=508b6ff8-601d-4901-a7a5-816141134054 · https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-decnupaz